Evidence map›Paper›PMID 26368860›Full record

ArticleGenomics2015

The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration.

Mathieu Lemire, Syed H E Zaidi, Brent W Zanke, Steven Gallinger, Thomas J Hudson, Sean P Cleary

Open access · greenAbstract read
In one paragraph

Article in Genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Genetic Regulation of DNA Methylation Yields Novel Discoveries in GWAS of Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Mathieu LemireOntario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada. Electronic address: mathieu.lemire@oicr.on.ca.
Syed H E ZaidiOntario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada. Electronic address: hassan.zaidi@oicr.on.ca.
Brent W ZankeDepartment of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada. Electronic address: bzanke@me.com.
Steven GallingerLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada; Division of General Surgery, Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada. Electronic address: steven.gallinger@uhn.on.ca.
Thomas J HudsonOntario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5S 1A1, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A1, Canada. Electronic address: tom.hudson@oicr.on.ca.
Sean P ClearyDepartment of Surgery, University Health Network, Toronto, Ontario M5G 2C4, Canada; Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario M5G 1X5, Canada. Electronic address: sean.cleary@uhn.ca.
Ontario Institute for Cancer Research · CAMount Sinai Hospital · CAUniversity Health Network · CAUniversity of Ottawa · CA

Funding

ONTARIO REGISTRY FOR STUDIES OF FAMILIAL COLON CANCERU01CA074783 · NCI · CANCER CARE ONTARIO · PI GALLINGER, STEVEN · 1997 to 2008
$12.5M
Colon Cancer Family Registry CohortUM1CA167551 · NCI · STANFORD UNIVERSITY · PI HAILE, ROBERT WILLIAM, JENKINS, MARK A · 2013 to 2017
$11.3M
The Colon Cancer Family Registry: OntarioU24CA074783 · NCI · CANCER CARE ONTARIO · PI GALLINGER, STEVEN · 2008 to 2011
$4.1M
Redox Regulation of Metastasis by Sod2K22CA095011 · NCI · ALBANY MEDICAL COLLEGE · PI MELENDEZ, JUAN ANDRES · 2002 to 2004
$446k
Canadian Institutes of Health Research 220561NCI NIH HHS CA-95-011NCI NIH HHS U01 CA074783NCI NIH HHS U24 CA074783NCI NIH HHS UM1 CA167551
6 · The paper itself

Abstract

Blood-based epigenome-wide association studies that aim at comparing CpG methylation between colorectal cancer (CRC) patients and controls can lead to the discovery of diagnostic or prognostic biomarkers. Numerous confounders can lead to spurious associations. We aimed to see if 5-fluorouracil (5-FU)/leucovorin chemotherapy administered to cases prior to the collection of their blood has an effect on methylation. 304 patients who received treatment and 273 who did not were profiled on the HumanMethylation450 array. Association tests were adjusted for confounders, including proxies for leukocyte cell counts. There were substantial methylation differences between these two groups that vanished once the leukocyte heterogeneity was accounted for. We observed a significant decrease of T cells in the treatment group (CD4+: p=10(-6); CD8+: p=0.036) and significant increase of NK cells (p=0.05) and monocytes (p=0.0006). 5-FU/leucovorin has no effect on global and local blood-based methylation profiles, other than through differences in the leukocyte compositions that the treatment induced.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCpG IslandsDNA MethylationEpigenesis, GeneticEpigenomicsFemaleFluorouracilHumansLeucovorinLeukocyte CountLeukocytesLinear ModelsMaleFluorouracilLeucovorin5-FluorouracilChemotherapyColorectal cancerHeterogeneityLeukocytesMethylation

Identifiers

PMID26368860
PMCPMC4722538
OpenAlexW1465670628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.